Giuseppe Corrias1, Sandra Huicochea Castellanos2, Ryan Merkow3, Russel Langan3, Vinod Balachandran3, Monica Ragucci4, Gabriella Carollo5, Marcello Mancini6, Luca Saba7, Lorenzo Mannelli8. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY; Department of Radiology, University of Cagliari, Cagliari, Italy. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 4. IRCCS SDN, Naples, Italy. 5. St. John's University, Queens, NY. 6. Istituto di Biostrutture e Bioimmagini, CNR, Naples, Italy. 7. Department of Radiology, University of Cagliari, Cagliari, Italy. 8. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY. Electronic address: mannellilorenzo@yahoo.it.
Abstract
RATIONALE AND OBJECTIVES: To determine the impact of second-opinion assessment on cancer staging and patient management in patients with pancreatic ductal adenocarcinoma. METHODS AND MATERIALS: This retrospective study was approved by our institutional review board with a waiver of informed consent. Second-opinion reports between January 1, 2009 and December 31, 2013, alongside outside reports for 65 consecutive cases of biopsy-proven pancreatic adenocarcinomas, were presented in random order to two experienced abdominal surgeons who independently reviewed them blinded to the origin of the report, images of the examinations, and patient identifier. Each surgeon filled in a questionnaire for each report recommending cancer staging and patient management. Recommended patient management and staging were evaluated against reference standards (actual patient management at 6 months following second-opinion assessment, and pathology or other clinical and imaging reference standards at 6 months or longer, respectively) using Cohen kappa. RESULTS: Cancer staging differed in 13% (9 of 65) of cases for surgeon 1 and in 18.4% (12 of 65) for surgeon 2. Patient management changed in 38.4% (25 of 65) of cases for surgeon 1 and in 20% (13 of 65) for surgeon 2. When compared to the pathologic staging gold standard, second opinion was correct in 85.7% (six of seven) of the time for both surgeons. Recommended patient management from second-opinion reports showed good agreement with the reference standard (weighted k = 0.6467 [0.4014-0.892] and weighted k = 0.6262 [0.3954-0.857] for surgeon 2). CONCLUSION: Second-opinion review by subspecialized oncologic radiologists can impact patient care, specifically in terms of management decision.
RATIONALE AND OBJECTIVES: To determine the impact of second-opinion assessment on cancer staging and patient management in patients with pancreatic ductal adenocarcinoma. METHODS AND MATERIALS: This retrospective study was approved by our institutional review board with a waiver of informed consent. Second-opinion reports between January 1, 2009 and December 31, 2013, alongside outside reports for 65 consecutive cases of biopsy-proven pancreatic adenocarcinomas, were presented in random order to two experienced abdominal surgeons who independently reviewed them blinded to the origin of the report, images of the examinations, and patient identifier. Each surgeon filled in a questionnaire for each report recommending cancer staging and patient management. Recommended patient management and staging were evaluated against reference standards (actual patient management at 6 months following second-opinion assessment, and pathology or other clinical and imaging reference standards at 6 months or longer, respectively) using Cohen kappa. RESULTS:Cancer staging differed in 13% (9 of 65) of cases for surgeon 1 and in 18.4% (12 of 65) for surgeon 2. Patient management changed in 38.4% (25 of 65) of cases for surgeon 1 and in 20% (13 of 65) for surgeon 2. When compared to the pathologic staging gold standard, second opinion was correct in 85.7% (six of seven) of the time for both surgeons. Recommended patient management from second-opinion reports showed good agreement with the reference standard (weighted k = 0.6467 [0.4014-0.892] and weighted k = 0.6262 [0.3954-0.857] for surgeon 2). CONCLUSION: Second-opinion review by subspecialized oncologic radiologists can impact patient care, specifically in terms of management decision.
Authors: Dustin M Walters; Damien J Lapar; Eduard E de Lange; Marc Sarti; Jayme B Stokes; Reid B Adams; Todd W Bauer Journal: Ann Surg Oncol Date: 2011-04-12 Impact factor: 5.344
Authors: E Belousova; G Karmazanovsky; A Kriger; D Kalinin; L Mannelli; A Glotov; N Karelskaya; O Paklina; A Kaldarov Journal: Clin Radiol Date: 2016-11-24 Impact factor: 2.350
Authors: Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Horacio Asbun; Andrew Bain; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; E Gabriela Chiorean; Vincent Chung; Brian Czito; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; Jeffrey Hardacre; William G Hawkins; Joseph Herman; Andrew H Ko; Srinadh Komanduri; Albert Koong; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Courtney Scaife; Sarah Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer Burns; Susan Darlow Journal: J Natl Compr Canc Netw Date: 2017-08 Impact factor: 11.908
Authors: Eric P Tamm; Aparna Balachandran; Priya R Bhosale; Matthew H Katz; Jason B Fleming; Jeffrey H Lee; Gauri R Varadhachary Journal: Radiol Clin North Am Date: 2012-04-06 Impact factor: 2.303
Authors: Sharyl J Nass; Christopher R Cogle; James A Brink; Curtis P Langlotz; Erin P Balogh; Ada Muellner; Dana Siegal; Richard L Schilsky; Hedvig Hricak Journal: J Clin Oncol Date: 2019-05-03 Impact factor: 44.544
Authors: Alexander Grogan; Benjamin Loveday; Michael Michael; Hui-Li Wong; Peter Gibbs; Benjamin Thomson; Belinda Lee; Hyun Soo Ko Journal: ANZ J Surg Date: 2022-05-25 Impact factor: 2.025